UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

 

 

 

 

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01.   Other Events.

 

On February 27, 2009, Biosense Webster, Inc., announced that the U.S. Food and Drug Administration has approved for marketing its NAVISTAR^® RMT THERMOCOOL^® Catheter for use with the Stereotaxis NIOBE^® platform. Stereotaxis (NASDAQ: STXS) (“Stereotaxis” or the “Company”) has partnered with Biosense Webster, Inc. in the development of ablation catheters used with its NIOBE^® Magnetic Navigation System. The NAVISTAR^® RMT THERMOCOOL^® Catheter for radiofrequency (RF) ablation is used with the NIOBE^® Magnetic Navigation System, which helps steer a catheter remotely and guide ablation to targeted areas that require treatment.

“NAVISTAR” and “THERMOCOOL” are registered trademarks of Biosense Webster, and “NIOBE” is a registered trademark of Stereotaxis.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.